definiens: shall mean all Intellectual Property Rights owned or held by Leicester, including witho ut limitation all such Intellectual Property Rights ar ising from the work of Dr. Schwaeble, Dr. Stover, a nd / or other Leicester employees as well as that acquired under an assignment agreement from Dr. Fujita, prio r to the Effective Date of this Agreement, or developed or obtained by Leicester after the Effective Date o f this Agreement both ( a ) independently of [COMPANY] ( as dete rmined by inventorship under US law with respect to any patents and patent applications ) and ( b ) indepe ndently of the Sponsored Research, provided however that in the event and to the extent that such indep endently developed Intellectual Property Rights ari se as the direct result of sponsorship by a not - for - profit en terprise in accordance with Section 4.3 herein, suc h independently developed Intellectual Property Right s shall be included within the scope of the license granted herein only if Leicester or Leicester emplo yee(s ) obtain an assignment or release of such independently developed Intellectual Property Right s from such not - for - profit enterprise, which assign ment or release Leicester shall exert all reasonable eff orts to obtain or to cause its employees to obtain, provided always that any of the Intellectual Property Rights described above in this section 1.4 are directly r elated to compositions, antibodies and/or methods for the inh ibition of MASP-2 and/or MAp19 and/or the diagnosis and/or treatment of MASP-2 or MAp19 mediated disord ers and/or deficiency syndromes, as well as methods, polynucleotides, polypeptides, sequences a nd tools related to the development and production of MASP-2 or MAp19 antibodies including without limita tion murine, human, humanized and recombinant antibodies, murine lines in which MASP-2 or MAp19 g enes have been knocked - out or knocked - in, and all Intellectual Property Rights in the subject matter disclosed or claimed in the draft patent applicatio n entitled GENETICALLY MODIFIED NON -HUMAN MAMMALS AND CELLS filed in the British Patent Office on 10 June 2004 and attached hereto as Exhibit A [ † ]